ICAppendicitis and other acute abdominal pain
been carried out on hospitalised patients.15 16 Given that patients are increasingly managed in primary, ambulatory and home settings, there is a need to also focus attention on community care contexts.

Prior to undertaking further primary work in this area, it is important to take stock of the current evidence base, reflect on the quality of the evidence, distil key findings that have the potential to provide both estimates on the frequency of medication errors and error-related ADEs, and understand the factors underpinning this important source of preventable harm. We will therefore undertake a systematic review investigating the incidence and prevalence of and risk factors for medication errors and error-related ADEs in community (ie, primary care, ambulatory and home) settings.

**Research question**

What are the incidence and prevalence of and risk factors for medication errors and error-related ADEs in primary care, ambulatory care and home settings?

**METHODS**

**Design**

We will undertake a systematic review and, if possible, a meta-analysis.

**Inclusion criteria**

Population-based cross-sectional and cohort studies will be eligible to estimate the incidence and prevalence of medication errors and ADEs; these study designs and case-control studies will be eligible to study risk factors for the development of error-related ADEs.

**Population**

The population of interest will be adults (≥18 years) who are dwelling in the community and living in their own homes without home healthcare or nursing at home. These patients may be self-managing, receiving care in primary care and ambulatory settings or any combination of the above.

**Exposures**

The exposure of interest is prescribed and/or over-the-counter medications.

**Outcomes**

The outcomes of interest are the incidence and prevalence of medication errors and ADEs, and risk factors for the development of medication errors and error-related ADEs. These errors may have occurred anywhere in the medicines’ management process.1 We will work with the definitions of medication errors and error-related ADEs employed in individual studies.

**Exclusion criteria**

1. Studies on illegal substance abuse, herbal products, home healthcare (ie, continuous medical and/or nursing care provided to patients in their own homes), nursing home, hospitalised in-patients or those managed in emergency department settings.
2. Paediatrics (<18 years).
3. Randomised controlled trials since these cannot be used to reliably assess the incidence and/or prevalence of the outcomes of interest.
4. Existing reviews since the focus is on the primary literature.
5. Studies focusing on specific medication errors or subgroups of populations.
6. Incompletely reported studies, for example, in the form of abstracts.

**Search strategy**

We will search the following biomedical databases for published research studies: Cumulative Index to Nursing and Allied Health Literature (CINAHL), EMBASE, Eastern Mediterranean Regional Office of the WHO (EMRO), MEDLINE, PsycINFO and Web of Science. These databases will be searched from January 1990 to December 2015; the start date has been chosen to reflect the time when patient safety came into the consciousness of policymakers, professionals and the public.17 In addition, we will search Google Scholar and contact an international panel of experts to search for unpublished and in progress work. The corresponding author of the eligible articles may be contacted if additional information is needed. The reference list of previous studies will be scrutinised for additional possible
eligible studies. No restriction on the language of publication will be employed.

Detailed search strategies are presented in online supplementary appendix 1.

**Study selection**

GA will search the databases. GA and a second reviewer will then independently screen the titles and abstracts for eligible studies according to the above detailed selection criteria. Full-text articles will be retrieved from selected studies and will be reviewed according to the selection criteria. Disagreements will be resolved by discussion between the reviewers or arbitration by a third reviewer if a decision cannot be reached. Each copy of the selected studies will be retrieved and the reason for excluding other studies will be clearly noted.

**Quality assessment**

The risk of bias assessments will be independently carried out on each study by two reviewers using the Critical Appraisal Skills Program quality assessment tool for cohort and case-control studies, and cross-sectional studies will be assessed using the Joanna Briggs Institute Critical Appraisal Checklist for Descriptive Studies. Any disagreements will be resolved by consensus or arbitration by a third reviewer if a decision cannot be reached. Each study will be graded as being at high, medium or low risk of bias.

**Data extraction**

Data will be extracted by two reviewers and recorded onto a customised data extraction sheet. Discrepancies will be resolved by discussion. The following information will be extracted:

1. Author, year;
2. Study design, study type (retrospective, prospective);
3. Population of interest;
4. Exposure of interest;
5. Outcomes of interest;
6. Main findings;
7. Conclusions;
8. Additional notes.

**Data analysis**

Data will be summarised in detailed data tables, which will include information on the incidence, prevalence, and relative risk and ORs, together with 95% CIs, for each study (where available). STATA (V.14) statistical software will be used to pool study data if this is considered both clinically and statistically appropriate. Meta-analyses will be undertaken using random-effects modelling. Sensitivity analyses will be undertaken by excluding studies judged to be at the highest risk of bias. Subgroup analyses will be undertaken comparing: adults (18–64 years) versus elderly (≥65 years) patients; and those who have recently been an inpatient or had a hospital visit (<30 days) versus those who have not had a recent hospital attendance (≥30 days).

If possible, funnel plots will be used to assess the presence of publication bias.

**Registration and reporting**

This systematic review will be registered with PROSPERO, an international prospective register of systematic reviews, and will be reported using Preferred Reporting Items for Systematic Reviews and Meta-Analyses and Meta-analysis Of Observational Studies in Epidemiology guidelines.

**DISCUSSION**

This systematic review will provide a comprehensive assessment of the epidemiology of medication errors and error-related ADEs in community settings. We anticipate reporting the findings from this study in the autumn of 2016.

**REFERENCES**


---

**Contributors**

GAA conceived the idea for this review. The protocol methods were developed in conjunction with AS and EG. GAA led the drafting of the manuscript and this was commented on critically by AS and EG.

**Funding**

The systematic review protocol is a part of GAA’s PhD study with The University of Edinburgh. King Saud University, College of Pharmacy funded the Scholarship. AS is supported by the Farr Institute.

**Competing interests**

None declared.

**Provenance and peer review**

Not commissioned; externally peer reviewed.

**Open Access**

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Acknowledgements**

The authors are grateful to Marshall Dozier for her help with formulating the search strategy, Rachel Faulkner-Jones for proofreading and the Farr Institute.

---

**Author affiliations**

1Centre for Population Health Sciences, Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, UK
2King Saud University, College of Pharmacy, Riyadh, Saudi Arabia
3Centre of Medical Informatics, Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, UK

---

**Funding**

This systematic review protocol is a part of GAA’s PhD study with The University of Edinburgh. King Saud University, College of Pharmacy funded the Scholarship. AS is supported by the Farr Institute.
24. What are over-the-counter (OTC) drugs and how are they approved? U.S. Food and Drug Administration (cited 19 October 2015). http://www.fda.gov/AboutFDA/Transparency/Basics/ucm194951.htm